首页> 美国卫生研究院文献>The Oncologist >Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)

【2h】

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)

机译：替莫唑胺加贝伐珠单抗治疗新诊断成胶质母细胞瘤的老年患者的不良表现：ANOCEF II期试验（ATAG）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Lessons Learned. class="unordered" style="list-style-type:disc" id="onco12378-list-0001">

Results suggest that the combination of bevacizumab plus temozolomide is active in terms of response rate, survival, performance, quality of life, and cognition in elderly patients with glioblastoma multiforme with poor performance status.

Whether this combination is superior to temozolomide alone remains to be demonstrated by a randomized study.

机译：得到教训。 class =“ unordered” style =“ list-style-type：disc” id =“ onco12378-list-0001”> <！-list-behavior = unordered prefix-word = mark-type = disc max-label- size = 0->

结果表明，贝伐单抗联合替莫唑胺在老年胶质母细胞瘤患者的反应率，生存率，表现，生活质量和认知方面均具有活性

这种组合是否优于单独的替莫唑胺仍需通过随机研究证实。

著录项

期刊名称 The Oncologist
作者
Germán Reyes‐Botero; *; Stéphanie Cartalat‐Carel; Olivier L. Chinot; Maryline Barrie; Luc Taillandier; Patrick Beauchesne; Isabelle Catry‐Thomas; Jérôme Barrière; Jean‐Sebastien Guillamo; Michel Fabbro; Didier Frappaz; Alexandra Benouaich‐Amiel; Emilie Le Rhun; Chantal Campello; Isabelle Tennevet; François Ghiringhelli; Marie‐Laure Tanguy; Karima Mokhtari; Jérôme Honnorat; Jean‐Yves Delattre;
展开▼
作者单位

展开▼
年(卷),期 2018(23),5
年度 2018
页码 524–e44
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG) [J] . Germ??n Reyesa??Botero, St??phanie Cartalata??Carel, Olivier L. Chinot, The oncologist . 2018,第5期

机译：替莫唑胺加贝伐珠单抗治疗新诊断成胶质母细胞瘤老年患者的不良表现：ANOCEF II期临床试验（ATAG）
2. Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG) [J] . Reyes-Botero German, Cartalat-Carel Stephanie, Chinot Olivier L., The oncologist . 2018,第5期

机译：替莫唑胺加上老年患有新诊断的胶质母细胞瘤患者的贝伐单抗和性能状况不佳：ANOCEF期二期试验（ATAG）
3. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: An ANOCEF phase II trial [J] . Pérez-LarrayaJ.G., DucrayF., ChinotO., Journal of Clinical Oncology . 2011,第22期

机译：替莫唑胺在新诊断成胶质母细胞瘤和低效状态的老年患者中的应用：ANOCEF II期临床
4. RISK-ADAPTED INTRAVENOUS MELPHALAN WITH ADJUVANT THALIDOMIDE AND DEXAMETHASONE FOR NEWLY DIAGNOSED UNTREATED PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS: INTERIM REPORT OF A PHASE II TRIAL [C] . RL Comenzo, P Zhou, L Reich, International Symposium on Amyloidosis . 2005

机译：风险适应的静脉内莫尔甘蔗用佐剂沙利度胺和地塞米松，用于新诊断的未经治疗的全身淀粉样蛋白症患者：II期试验的中期报告
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. ACTR-89. KARNOFSKY PERFORMANCE STATUS AND STEROID USE IN PHASE II TRIAL OF BEVACIZUMAB AND TEMOZOLOMIDE FOR UPFRONT TREATMENT OF ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA [O] . Hye Hyun Bahng, Stacey Green, Albert Lai, 2017

机译：ACTR-89。贝伐单抗和替莫唑胺二期试验卡诺夫斯基治疗状态和类固醇激素用于新诊断成胶质细胞瘤的老年患者的超声治疗
7. Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG) [O] . Germán Reyes‐Botero, Stéphanie Cartalat‐Carel, Olivier L. Chinot, 2018

机译：替莫唑胺类加上老年患有新诊断的胶质母细胞瘤和性能状况不佳的患者：ANOCEF期间试验（ATAG）

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)

摘要

著录项

相似文献

相关主题

期刊订阅